Seasonal Influenza Vaccine Demand to Reach 158 million in 2022, Forecasts GlobalData

20 Feb 2013 • by Natalie Aster

The US demand for influenza vaccines will remain high in the coming decade, following a post-flu pandemic spike. Seasonal influenza vaccine demand will increase from the 142 million expected for 2012 to 158 million in 2022, representing an Annual Growth Rate (AGR) of 1.2%, according to the report "EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022" by GlobalData.

Report Details:

EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
Published: November, 2012
Pages: 69
Price: US$ 6,995.00

After the H1N1 (originally named ‘swine flu’) pandemic claimed thousands of lives across the US in 2009, the number of those vaccinated annually climbed significantly – from 24% in 2007 to 41% in 2010 for citizens aged 5-64 years – according to the US Centers for Disease Control and Prevention (CDC).

The new GlobalData reports says that the primary driver for the predicted growth in influenza vaccine demand will be a general increase in the US population and the corresponding rise in those classed as high-risk, such as the elderly or those with pre-existing conditions.

Of the nine major markets explored in the report (the US, Japan, India, China, and the top five European economies), India is expected to exhibit the greatest surge in vaccine demand over the next 10 years, climbing at a AGR of 2.1%. However, despite this relative growth, GlobalData estimates that the percentage of influenza-vaccinated citizens in the country will total a meager 1.7% of the population by 2022.

More information can be found in the report “EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022” by GlobalData.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970